NIHR EME award a first for Wales13 Feb 2018
Professor Colin Dayan and Professor John Gregory of Cardiff University, with support from the Diabetes Research Unit Cymru and the Swansea Trials Unit, have recently received a National Institute of Health Research (NIHR) five-year grant.
The funding from the NIHR's Efficacy and Mechanism Evaluation (EME) programme is the first such bid led from Wales and will be used to evaluate the utility of a monoclonal antibody (ustekinumab), licensed for use in the treatment of psoriasis and Crohn's disease, as a means of preserving insulin producing cells in young people with recent onset type I diabetes.
Across the UK there are approximately 3000 people a year diagnosed with new onset type I diabetes with over half of them being young people and children under the age of eighteen.
The study - USTEKID - will be carried out across the UK utilising, amongst others, the network of experts and facilities that make up the Type 1 Diabetes UK Immunotherapy Consortium.
A video aimed at explaining the study to young people in everyday terms and designed to encourage them to participate in the study is now being finalised.
If you would like more details concerning this trial, contact Dr Kym Thorne, USTEKID trial manager at email@example.com.